

# Benjamin M Parsons

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5093058/publications.pdf>

Version: 2024-02-01

19  
papers

473  
citations

949033

11  
h-index

939365

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

882  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	3.2	22
2	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	1.5	20
3	Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. <i>JCO Precision Oncology</i> , 2021, 5, 1312-1324.	1.5	15
4	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	2.1	6
5	Utilization of Surgery and Its Impact on Survival in Patients With Early Stage Small-cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2020, 21, 186-193.e2.	1.1	15
6	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	2.5	22
7	Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. <i>Experimental and Molecular Pathology</i> , 2019, 110, 104260.	0.9	8
8	MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 346-355.	1.9	24
9	Does Timing of Inferior Vena Cava Filter Retrieval Planning Impact Retrieval Rates? A Comparison of Planning Before or After Hospital Discharge. <i>Wisconsin Medical Journal</i> , 2019, 118, 30-34.	0.3	1
10	A Strategy for Changing Adherence to National Guidelines for Decreasing Laboratory Testing for Early Breast Cancer Patients. <i>Wisconsin Medical Journal</i> , 2018, 117, 68-72.	0.3	2
11	Fewer Reoperations After Lumpectomy for Breast Cancer with Neoadjuvant Rather than Adjuvant Chemotherapy: A Report from the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2017, 24, 1507-1515.	0.7	19
12	Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database*. <i>Leukemia and Lymphoma</i> , 2017, 58, 2080-2088.	0.6	57
13	Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	6
14	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	18
15	21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 315-326.	1.1	18
16	A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. <i>Blood</i> , 2012, 119, 692-695.	0.6	138
17	Analysis of very elderly (>80 years) non-Hodgkin lymphoma: impact of functional status and comorbidities on outcome. <i>British Journal of Haematology</i> , 2012, 156, 196-204.	1.2	81
18	Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era. <i>Blood</i> , 2011, 118, 2625-2625.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,. Blood, 2011, 118, 3668-3668.	0.6	0